BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 8315425)

  • 1. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
    J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
    J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
    Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of advanced sarcomas of bone and soft tissue.
    Antman KH
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
    J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dana-Farber Cancer Institute studies in advanced sarcoma.
    Antman KH; Elias A
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
    J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR
    J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
    Weh HJ; Agarwal K; Zornig C; Schwarz R; Dietel M; Hossfeld DK
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S189-93. PubMed ID: 8453696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
    Elias AD; Antman KH
    Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of advanced soft-tissue sarcomas.
    Antman KH; Elias AD
    Semin Surg Oncol; 1988; 4(1):53-8. PubMed ID: 3281212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
    Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
    Weh HJ; Zügel M; Wingberg D; Schwarz R; Zornig C; Dietel M; Hossfeld DK
    Onkologie; 1990 Dec; 13(6):448-52. PubMed ID: 2128712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
    J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Soft tissue sarcoma: postoperative chemotherapy].
    Goto T; Kosaku H; Kobayashi H; Hozumi T; Kondo T
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1324-30. PubMed ID: 15446551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
    González-Manzano R; Vieitez JM; Tangco E; Fernandez de Alava E; Herranz P; Garcia-Foncillas J
    Am J Clin Oncol; 1993 Aug; 16(4):332-7. PubMed ID: 8328412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.
    Blum RH; Edmonson J; Ryan L; Pelletier L
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S238-40. PubMed ID: 8453706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.